Adaptive Biotechnologies: Hold Despite Weak Financials As Catalysts Are Ahead – Adaptive Biotechnologies Corporation (NASDAQ:ADPT)


Investment Thesis Adaptive Biotechnologies Corporation (ADPT) has declined ~36% since its IPO in late July last year, at a time Nasdaq Biotechnology Index has risen ~9%. Despite its foray into therapeutics and early diagnostics, the company’s tissue-based cancer detection is still confined to a few less common cancers. Meanwhile, itsRead More →

Blueprint Secures Favorable FDA Approval For PDGFRA Exon 18 Mutant GIST – Blueprint Medicines Corporation (NASDAQ:BPMC)


Introduction Blueprint Medicines (BPMC) is a precision oncology biotechnology company. Lead indications include gastrointestinal stromal tumors (GISTs) and systemic mastocytosis (SM). Blueprint’s lead drug, avapritinib, targets KIT and PDGFRA kinases, making it an appropriate candidate for GISTs. GIST Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of theRead More →